FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 545 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Embrace Your Inner Flexibility March 29, 2021 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ January 17, 2022 Woman with Breast Cancer May Have Saved Her Twin’s Life by... October 16, 2020 The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 Load more HOT NEWS New Research Looks for More Effective Breast Cancer Treatments for Black... Philanthropist Simon Collins: “I realised I could make a difference by... Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... In Memory of Håkan Mellstedt: Former ESMO President
